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606Objective: The resection of two lobes for non–small cell lung cancer has the potential for significant morbidity
and mortality as well as a negative impact on survival. The purpose of this study is to analyze our bilobectomy
experience.
Methods: Age, gender, diagnosis, bilobectomy type, bilobectomy indication, operative technique, pathologic
condition, major complications, stage, and survival were reviewed from 1984 through 2007. Major complications
were compared by Fisher’s exact testing. Kaplan–Meier survival curves were compared by log–rank and likeli-
hood ratio analysis.
Results: Bilobectomies were performed on 92 patients with non–small cell lung cancer. A total of 35 upper–mid-
dle and 57middle–lower bilobectomies were performed. Indications for bilobectomywere bronchial involvement
(n ¼ 49), extension across the fissure (n ¼ 36), or other reasons (n ¼ 7). The 5-year survival for all patients was
42%. Significant differences in survival were observed among the different stages (stage I, 65%; stage II, 42%;
stage III, 13%; P<.0001). Squamous cell carcinomas had a higher 5-year survival than adenocarcinomas (54%
vs 32%), a difference that approached significance by log–rank test (P<.079) and reached significance by likeli-
hood ratios (P< .048). When bilobectomy was performed for extension across the fissure, survival approached
significance for squamous cell carcinomas (71%) over adenocarcinomas (42%) by log–rank test (P< .089) and
was significant by likelihood ratio (P<.048) when comparing survival between adenocarcinoma and squamous
cell carcinoma. Multivariate analysis demonstrated that increasing age (P ¼ .0102) and upper&middle bilobec-
tomy (P ¼ .0285) adversely affected 5-year survival, whereas early-stage disease (P ¼ .0245) beneficially af-
fected 5-year survival.
Conclusion: Bilobectomy can be performed with acceptable morbidity and mortality. Survival relates to disease
stage. Optimal survival benefit occurs when the indication for bilobectomy is squamous cell carcinoma extending
across the fissure. (J Thorac Cardiovasc Surg 2010;139:606-11)It is often accepted that the removal of two pulmonary lobes
on the right side, otherwise referred to as a bilobectomy, has
an acceptable morbidity and mortality profile. On the basis
of the extent of resection, it can be assumed that this morbid-
ity and mortality is intermediate between a lobectomy and
pneumonectomy. Presumably, the long-term survival is
also reflective of the stage of disease that warranted a bilo-
bectomy. It is unclear whether the indication for the bilobec-
tomy both justifies and affects the performance of this
operation. The primary objective of this study was to deter-
mine the survival associated with bilobectomy for non–e Department of Cardiothoracic–Vascular Surgery, Rush University Medical
r, Chicago, Ill.
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The Journal of Thoracic and Cardiovascular Surgsmall cell lung cancer (NSCLC). The secondary purpose
was to identify certain clinical factors that affected survival
and morbidity.METHODS
Clinical records of patients who underwent a bilobectomy at a single
academic institution between January 1984 and December 2007 were
reviewed. Patients were chosen on the basis of (1) having undergone
a successful bilobectomy, (2) having a diagnosis of NSCLC, and (3) having
undergone a complete resection of their disease. Patients excluded were
those who (1) had a diagnosis other than NSCLC (eg, metastases, neuroen-
docrine carcinoma, benign disease), (2) had a resection of fewer than two
anatomic lobes, and (3) had a resection of greater than two anatomic lobes.
Institutional review board approval was obtained to perform this retrospec-
tive investigation.
The age, gender, type of bilobectomy (upper and middle [UM] vs middle
and lower [ML]), stump closure technique, histopathologic diagnosis and
stage, perioperative mortality, and postoperative complications were re-
corded. Tumor stages, irrespective of the date of operation, were adjusted
to be in accordance with the current sixth edition of the American Joint
Commission for Cancer TNM classification scheme. Operative reports
were reviewed to identify the indications for bilobectomy. Bilobectomies
were divided into two major categories: (1) those performed secondary to
extension across the fissure or (2) those performed secondary to bronchusery c March 2010
TABLE 1. Indication for bilobectomy
Kim et al General Thoracic SurgeryIndication No. (%)Abbreviations and AcronymsIntrinsic or extrinsic bronchial involvement 49 (53%)ADC ¼ adenocarcinoma
Extension across the fissure 36 (39%)BPF ¼ bronchopleural fistula
Vascular injury (4%)ML ¼ middle and lower
Multiple nodules 3 (3%)NSCLC ¼ non–small cell lung cancerSQC ¼ squamous carcinomaSUM ¼ upper and middleG
Tinvolvement. Identification of extension of tumor across the fissure was rel-
atively straightforward, whereas classification of bronchial involvement
was more complex. Tumors classified under this indication included those
that had (1) internal extension of the tumor proximally or distally, (2) exter-
nal involvement of the tumor encroaching on the bronchus, and (3) involve-
ment of the lymph node between the upper lobe andmiddle lobe bronchus or
between the middle lobe and lower lobe bronchus.
Statistical Methods
Kaplan–Meier 5-year survival curves were generated for the overall
NSCLC population. Kaplan–Meier 5-year survival curves were also gener-
ated for univariate comparisons between different subsets, including gender,
UM versus ML bilobectomies, stages, nodal status, indications for bilobec-
tomy, and histopathologic subtypes. Additional subset analysis was per-
formed to compare survival between histopathologic subtypes while
adjusting for stage and indication for bilobectomy. Log–rank and likelihood
ratio analysis were used to compare survivals. The log–rank test (log rank),
based on the Mantel–Haenszel statistic, is a nonparametric test that com-
pares the observed and expected number of events at each observed event
time. The likelihood ratio test (2Log [LR]) is based on the parametric ex-
ponential model.1 In this article, both the log–rank and the likelihood ratio
tests were used with the understanding that the latter used a more stringent
statistical model for the hazard functions. Fisher’s exact testing was used to
compare the incidence of major complications. Multivariate analysis of 5-
year survival was performed using the Cox proportional hazards regression
model. The statistical analysis was performed with SAS version 9.1 (SAS
Institute, Inc, Cary, NC) software.
RESULTS
Univariate Analysis
Bilobectomies were performed on 92 patients having
NSCLC (45 adenocarcinomas [ADC], 39 squamous carci-
nomas [SQC], and 8 others—4 adenosquamous and 4 large
cell carcinomas). A total of 89 bronchial stumps were closed
by staples versus 3 closed by suture. Bronchial stump cover-
age or space reduction techniques were not used. There were
35 UM and 57 ML bilobectomies performed. Indications for
bilobectomy included intrinsic or extrinsic bronchial in-
volvement of the tumor (n¼ 49), extension across the fissure
(n ¼ 36), or other reasons such as vascular involvement or
multiple nodules (n ¼ 7) (Table 1). Intrinsic involvement
of the bronchi (38/49) constituted the majority of the tumors
that required bilobectomy for this indication. Only 22% (11/
49) of the bilobectomies were performed for extrinsic or
nodal involvement of the bronchi. The mean age of the 92
patients with NSCLC was 65  11 years (range, 37–92
years).The Journal of Thoracic and CaMajor complications included pneumonia or retained
secretion requiring intervention (21/92), supraventricular
tachyarrhythmia (11/92), prolonged air leak (8/92),
empyema (3/92), adult respiratory distress syndrome (2/
92), thromboembolic complications (2/92), stroke (2/92),
stump-related bronchopleural fistula (BPF) (1/92), chylo-
thorax (1/92), myocardial infarction (1/92), and recurrent
laryngeal nerve injury (1/92) (Table 2). There was one
stump-related BPF that developed in an ML lobe stump
closed by suture in a patient who had undergone preoperative
concurrent neoadjuvant chemoradiation. This BPFwas small
and treated successfully with the bronchoscopic instillation
of fibrin glue. The remainder had no bronchial complications.
There were 4 (4.3%) deaths from pneumonia, empyema,
adult respiratory distress syndrome, and pulmonary embolus.
The incidence of major complications among UM versus
ML bilobectomies was 31% (11/35) and 51% (29/57), re-
spectively (P ¼ not significant). When complications were
analyzed among the indication for bilobectomies, the inci-
dence of complications was 55% (27/49) for those per-
formed for intrinsic or extrinsic bronchial involvement
versus 31% (11/36) for those with extension across the fis-
sure. When the indication for bilobectomy was extension
across the fissure, there was a statistically significant in-
crease in the incidence of complications when compared
with all other indications combined (P ¼ .011).
Stapled closure of the bronchial stumps was performed on
89 patients with NSCLC. The remaining 3 patients under-
went a sutured closure of their bronchial stumps. All 3 of
these patients, underwent an ML bilobectomy. Sutured
closure was performed in these patients owing to concerns
regarding the proximal extent of the tumor, which warranted
an opening of the bronchus to ensure clear margins before
closure. Therefore, a stapled closure was not initially at-
tempted. One of these 3 patients had a BPF and retained se-
cretions requiring bronchoscopic intervention, and another
had a persistent air leak requiring prolong chest tube drain-
age. The remaining patient did not have a complication. No
BPFs developed among the remaining 89 patients with sta-
pled closures. Space reduction techniques, such as pleural
tenting or pneumoperitoneum, were not routinely used.
Furthermore, stump coverage techniques also were not
routinely used.
Chemoradiation was performed in the neoadjuvant setting
in 11 patients. Of these 11 patients, 7 underwent an operative
procedure to secure a tissue diagnosis. Six patientsrdiovascular Surgery c Volume 139, Number 3 607
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FIGURE 1. Overall 5-year survival of all patients undergoing bilobectomy
was 42%. The broken lines represent the 95% confidence intervals. The
numbers in parentheses represent those at risk.
FIGURE 2. Five-year survival stratified by stage of NSCLC. Five-year
survival progressively decreases with advancing stage as expected: stage
I, 65%; stage II, 42%; stage III, 13%. The additional lines outside the bold-
face lines represent the 95% confidence intervals. The numbers in parenthe-
ses represent those at risk.
TABLE 2. Major complications among the 92 patients
Complication No. (%)
Pneumonia or retained secretion 21 (23%)*
Arrhythmia 11 (12%)
Prolonged air leak 8 (9%)*
Empeyma 3 (3%)
Adult respiratory distress syndrome 2 (2%)
Thromboembolus 2 (2%)
Stroke 2 (2%)
Bronchopulmonary fistulas 1 (1%)*
Chylothorax 1 (1%)
Myocardial infarction 1 (1%)
Recurrent laryngeal nerve injury 1 (1%)*
Some patients had more than 1 complication. *Includes 1 with a sutured bronchus
(1 sutured closure with 2 complications).
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itive for mediastinal lymph node involvement and 1 was neg-
ative for disease. One patient had a supraclavicular lymph
node thatwas positive before chemoradiation.Despite a defin-
itive course of treatment with an interval response to therapy,
he had a local recurrence and, therefore, underwent bilobec-
tomy. Of the remaining 4 patients, 3 had enlarged lymph no-
des diagnosed primarily by the computed tomographic scan
criterion of larger than 1 cm on short axis. In reality, all 3
of these patients had lymphadenopathy that was much greater
than this criterion. One last patient underwent chemoradiation
owing to chest wall involvement. Three of these 11 patients
had a complication (BPF, n ¼ 1; prolonged air leak, n ¼ 1;
and pulmonary secretions requiring intervention, n ¼ 1). In
this subset of patients, stump coverage also was not routinely
used.
Overall 5-year survival for the 92 patients with NSCLC
was 42% (Figure 1). No survival differences were observed
when comparing gender and type of bilobectomy (UM vs
ML). As expected, significant differences in survival by
log–rank and likelihood ratios were observed among the dif-
ferent stages (stage I, 65%; stage II, 42%; stage III, 13%;
P< .0001) (Figure 2). Individually, significant TNM stage
survival differences were observed only among the different
N groups and not among the different T groups. Five-year
survival was better for N0 versus N1 patients (62% vs
35%; P< .020) and N0 versus N2 (62% vs 8%; P<
.001) patients. The difference between N1 and N2 patients
approached significance (35% vs 8%; P<.057) (Figure 3).
When overall survival was compared for all NSCLCs, no
significant difference in survival was observed when com-
paring extension across the fissure to bronchial involvement.
However, when only tumor histopathologic type was evalu-
ated, SQCs had a higher 5-year survival than ADCs (54% vs
32%); this difference approached significance by log rank
(P< .079) and reached significance by likelihood ratios
(P< .048). When tumor histopathologic type was stratified
by indication for bilobectomy, neither ADCs nor SQCs608 The Journal of Thoracic and Cardiovascular Surgdemonstrated a difference in survival when the resection
was performed for bronchial involvement or extension across
the fissure. The 5-year survival for SQCs, however, when
evaluated for extension across the fissure (71%) versus for
bronchial involvement (46%), approached significant differ-
ence by likelihood ratio (P¼ .067). Alternatively, when eval-
uating the indication for bilobectomy stratified by tumorery c March 2010
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FIGURE 3. Five-year survival stratified by nodal status: (N0 ¼ no nodes,
62%; N1 ¼ ipsilateral hilar nodes, 35%; N2 ¼ ipsilateral mediastinal no-
des, 8%. The additional lines outside the boldface lines represent the
95% confidence intervals. The numbers in parentheses represent those at
risk.
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FIGURE 4. Comparison of 5-year survival for adenocarcinomas (ADC,
42%) versus squamous cell carcinomas (SQC, 71%) when the indication
for bilobectomy was extension across the fissure, P¼ .048 by likelihood ra-
tio (2Log [LR]). The additional lines outside the boldface lines represent
the 95% confidence intervals. The numbers in parentheses represent those
at risk.
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Shistopathologic type, no difference in survival was observed
between ADCs and SQCs when bilobectomy was performed
for bronchial involvement. However, when bilobectomywas
performed for extension across the fissure, the survival dif-
ference approached significance for SQCs (71%) over
ADCs (42%) by log-rank analysis (P<.089) andwas signif-
icant by likelihood ratio (P< .048) (Figure 4).
In another subset analysis, the 5-year survivals for ADCs
and SQCs were compared when controlling for both stage
and indication. No significant differences in survival be-
tween ADCs and SQCs were observed when adjusting for
individual stage and indication for bilobectomy. The reason
for this most likely was because there were too few numbers
for comparison, thereby making for a statistically weak com-
parison. Even when stage I and II NSCLCs were grouped
into early-stage NSCLCs and stage III and IV NSCLCs
were grouped into late-stage NSCLCs, a trend toward a dif-
ference in survival was not observed between ADCs and
SQCs. The lone exception was found within early-stage
NSCLCs when bilobectomy was performed for extension
across the fissure only. In this subset, a trend toward im-
proved survival for SQCs (75%) over ADCs (46%) was ob-
served by likelihood ratios (P ¼ .099) (Figure 5).0 12 24 36 48 60 
months 
FIGURE 5. Comparison of 5-year survival for early-stage adenocarci-
nomas (ADC, 46%) versus early-stage squamous cell carcinomas (SQC,
75%) when the indication for bilobectomy was extension across the fissure,
P¼ .099 by likelihood ratio (2Log {LR}). The additional lines outside the
boldface lines represent the 95% confidence intervals. The numbers in
parentheses represent those at risk.Multivariate Analysis
Multivariate analysis demonstrated that increasing age
(P¼ .0397) and UM bilobectomy (P¼ .0148) adversely af-
fected the 5-year survival. On the other hand and as would be
expected, a pathologically negative lymph node status (P ¼
.0032) beneficially affected the 5-year survival. Similarly,The Journal of Thoracic and Caearly stage I disease (P ¼ .0557) approached significance
in positively affecting 5-year survival.DISCUSSION
It has been suggested that bilobectomies may be associ-
ated with increased morbidity and mortality because of therdiovascular Surgery c Volume 139, Number 3 609
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rather than resection of a nonanatomic portion of an adjacent
lobe.2 In fact, the performance of a bilobectomy has been
shown to be a risk factor for increased morbidity and mortal-
ity in the settings of sleeve resection3 and postinduction
chemotherapy.4 In this study, chemoradiation was not asso-
ciated with a significantly higher incidence of complications.
The overall perioperative mortality risk associated with
bilobectomy is reported to be typically between 3.5% and
6%,5-8 although there have been reports of higher perioper-
ative mortality rates within 60 days.9 The overall periopera-
tive mortality of 4.3% in this series was within the cited
range.
In 1991, Vester and associates10 reported on a series
from our institution of over 2000 pulmonary resections,
of which more than 20% involved a sutured bronchial clo-
sure, with an overall incidence of BPFs of 1.6%. Nine
BPFs occurred after bilobectomy with sutured closure of
the bronchus. In this current series, only 3 patients under-
went a sutured closure of the bronchus. Interestingly,
a stump-related complication developed in 1 of these 3 pa-
tients. The discrepancy noted between this study and the
earlier study can be reconciled by the fact that the patients
in this series were clinically different from patients ana-
lyzed earlier. It could be argued that had the earlier group
of patients undergone a stapled closure with the modern
day stapling devices, the incidence of BPFs may have
been less. Routine coverage of the bronchial stump was
not performed in this series. The incidence of BPF in this
study was comparable with that reported previously.11-13
Interestingly, the BPF that developed in this study occurred
in a patient undergoing an ML bilobectomy. This has been
cited as a risk factor in their development.13
Decreased survival has been associated when bilobec-
tomy is performed for NSCLC.14 Bilobectomy appears to
have its most negative impact in elderly patients more than
70 years of age.15,16 The mean age of the patients in this se-
ries approximated the aforementioned age. In this series, tu-
mors crossing the fissure were associated with an improved
outcome when compared with those with bronchial involve-
ment. Interestingly, neither the old nor the new staging sys-
tems specifically addresses this in their staging schema.
Although the issues of visceral pleural involvement and
the sequelae of extrinsic or intrinsic lobar involvement are
included in the staging system, they do not specifically
address tumors that extend across the fissure.
Designating interlobar pleural involvement as T2 or T3 le-
sions is controversial.2,17-19 NSCLCs crossing the fissure
into an adjacent lobe have been shown to share a survival
profile similar to that of classic T3 tumors.2,17 This is in con-
tradistinction to others who have suggested that interlobar
pleural involvement warrants a T2 designation, particularly
when the lesions can be stratified to SQCs extending across
the fissure.18,19 The findings of the study reported in this ar-610 The Journal of Thoracic and Cardiovascular Surgticle support the contention that SQCs are associated with
better long-term survival than other histopathologic sub-
types with similar or different indications for bilobectomy.
The extent of surgery, like the T designation, also is a con-
troversial issue. In cases in which the extent of invasion is
relatively minimal,2 lesser resections of the adjacent in-
volved lobe have been performed. In circumstances with tu-
mor crossing the fissure into the adjacent lobe, lesser
resection has still been advocated largely because stage-spe-
cific survival is not different between additional lobar versus
sublobar resection.17-19 Demir and associates2 demonstrated
that bilobectomy or lobectomy with sublobar resection was
associated with significantly better survival when compared
with pneumonectomy for adjacent lobar involvement. Un-
fortunately, the issue of sublobar versus lobar resection re-
mains unanswered inasmuch as there are no randomized
controlled data supporting either strategy.
In general, the results of the multivariate analysis were as
expected in that increased age negatively affected long-term
survival whereas early stage of disease positively affected
long-term survival. Although the indication for bilobectomy
did not affect 5-year survival, the performance of a UM bi-
lobectomy adversely affected 5-year survival. This finding
on multivariate analysis was perplexing and prompted an-
other review of the data (not shown), which did not find
a disproportionate or significant number of patients who
had advanced age, advanced disease, or any other clinical
factor that would indicate this result. Also, the univariate
analysis did not mirror these results. This unexpected finding
may speak to the other pathophysiologic reasons that may
serve as the basis for future studies.
In this article, there were 3 patients with synchronous pri-
mary lung cancers that warranted bilobectomy. Deschamps
and colleages20 showed that bilobectomy for this indication
was not only safe, but justified. Bilobectomy for this indica-
tion was associated with an increased likelihood of perioper-
ative mortality, but the 5-year survival was similar to that for
lobectomy for this indication and statistically different from
that for pneumonectomy.15 The new staging system down-
stages these ipsilateral multilobar nodules into the T4 desig-
nation, rather than classifying this subset as M1 disease, and
also places this group in the stage IIIA rather than the stage
IV prognostic category, if there is no N2 or N3 involve-
ment.21 This reorganization suggests that resectional therapy
plays a role in this subset of patients, and therefore a bilobec-
tomy may be justified. Interestingly, the new staging system
does not account for extension across the fissure into an ad-
jacent lobe. This is the very group, when the primary histo-
logic type is SQC, that appears to benefit the greatest from
bilobectomy. Further studies for this indication comparing
a nonanatomic (wedge) resection of lesser anatomic resec-
tion (segmentectomy) versus an anatomic (lobectomy) re-
section may help to elucidate a potential substage in the
new staging system.ery c March 2010
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limitation of this study inasmuch as it resulted in the inability
to make certain delineations such as that between a larger
central mass that crossed the fissure versus one that arose
from the two lobar bronchi. However, the medical records,
including the rationale for operation and the operative
reports, were evaluated carefully and closely to try to best
discern between a ‘‘bronchial involvement’’ versus an ‘‘ex-
tension across the fissure’’ indication for bilobectomy. Fur-
thermore, in our experience, when a central tumor becomes
so large as tomake the distinction between bronchial involve-
ment and fissure extension difficult, a more extensive opera-
tion, such as a pneumonectomy or sleeve resection, is
required, thereby excluding bilobectomy as an option. Simi-
larly, the distinction between extrinsic or nodal involvement
was not easily discernible inasmuch as nodal involvement
that could not be dissected free on its own was considered
equivalent to extrinsic bronchial involvement. In our experi-
ence, an extensive nodal dissection is performed throughout
any anatomic resection. Therefore, if there is a significant
burden of disease that prevents dissection of the lymph nodes
separately from the bronchus, then this level of disease is
tantamount to extrinsic bronchial involvement. Several sub-
group analyses were performed on the basis of the indication
for bilobectomy. Qualitatively, the results of these subgroup
analyses were similar in that they demonstrated a survival
advantage of patients undergoing bilobectomy for SQCs
that extended across the fissure. Unfortunately, the differ-
ences observed in the subgroup analyses did not reach signif-
icance, and this is indicative of the relatively small numbers
in subgroups being compared. Last, the statistical analysis
performed did not include risk adjustments and, therefore,
may have included survival analyses of a heterogeneous
population. Despite this, we believed that patient selection
was comparable with that which is practiced in other aca-
demic institutions and, ultimately, the indication for bilobec-
tomy was the main discerning factor for the performance of
this operation, and not other preoperative factors.
Bilobectomies have a morbidity and perioperative mortal-
ity profile intermediate between lobectomy and pneumonec-
tomy, but generally approximate historical figures for the
former more than the latter. Furthermore, this profile shows
that the incidence of complications including a lower inci-
dence of BPF is acceptable when compared historically
with pneumonectomy. Ultimately, the findings of this inves-
tigation indicate that bilobectomy is a safe operation. The
survival suggests that it is an adequate oncologic procedure.
Finally, the indication for bilobectomy, particularly if it is anThe Journal of Thoracic and CaSQC that extends across the fissure, may be associated with
the most benefit when performing bilobectomy.References
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